Relationships among tumor load, route of tumor inoculation, and response to immunochemotherapy in a murine lymphoma model

P. Marconi, A. Cassone, M. Baccarini, L. Tissi, E. Garaci, E. Bonmassar, L. Frati, F. Bistoni

Research output: Contribution to journalArticle

Abstract

The combined effects of nonspecific immunostimulation with Candida albicans (CA) and chemotherapy were studied in (BALB/cCr x DBA/2Cr)F1 and (C57BL/6Cr x DBA/2Cr)F1 mice bearing virus-induced LSTRA lymphomas. Paradoxically, animals treated with a relatively high number of tumor cells responded better to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea) (BCNU) than those challenged with a low number of tumor cells. However, the majority of mice subjected to low initial tumor load were cured when they were treated with chemotherapy plus booster injection of CA at a relatively 'late' stage of the disease, i.e., when high tumor load was present in tumor-bearing hosts. It has been shown that this phenomenon, provisionally called high tumor load protection, occurs when the animals are challenged ip but not when they are challenged iv with the tumor and is abolished by total-body γ-irradiation. Moreover, marked host protection can be attained when immunostimulated mice, inoculated iv with lymphoma cells, are subjected to simultaneous challenge with high inocula of the same tumor ip, followed by BCNU administration. These data stress the importance of the peritoneal cavity of successful CA plus drug treatment and suggest that optimal tumor 'antigen load' should be present at the time of CA and/or BCNU administration.

Original languageEnglish
Pages (from-to)299-307
Number of pages9
JournalJournal of the National Cancer Institute
Volume71
Issue number2
Publication statusPublished - 1983

Fingerprint

Carmustine
Tumor Burden
Lymphoma
Candida albicans
Neoplasms
Cell Count
Drug Therapy
Whole-Body Irradiation
Peritoneal Cavity
Neoplasm Antigens
Immunization
Viruses
Injections
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relationships among tumor load, route of tumor inoculation, and response to immunochemotherapy in a murine lymphoma model. / Marconi, P.; Cassone, A.; Baccarini, M.; Tissi, L.; Garaci, E.; Bonmassar, E.; Frati, L.; Bistoni, F.

In: Journal of the National Cancer Institute, Vol. 71, No. 2, 1983, p. 299-307.

Research output: Contribution to journalArticle

Marconi, P, Cassone, A, Baccarini, M, Tissi, L, Garaci, E, Bonmassar, E, Frati, L & Bistoni, F 1983, 'Relationships among tumor load, route of tumor inoculation, and response to immunochemotherapy in a murine lymphoma model', Journal of the National Cancer Institute, vol. 71, no. 2, pp. 299-307.
Marconi, P. ; Cassone, A. ; Baccarini, M. ; Tissi, L. ; Garaci, E. ; Bonmassar, E. ; Frati, L. ; Bistoni, F. / Relationships among tumor load, route of tumor inoculation, and response to immunochemotherapy in a murine lymphoma model. In: Journal of the National Cancer Institute. 1983 ; Vol. 71, No. 2. pp. 299-307.
@article{b551a557bdf64dac88202ce0862002fe,
title = "Relationships among tumor load, route of tumor inoculation, and response to immunochemotherapy in a murine lymphoma model",
abstract = "The combined effects of nonspecific immunostimulation with Candida albicans (CA) and chemotherapy were studied in (BALB/cCr x DBA/2Cr)F1 and (C57BL/6Cr x DBA/2Cr)F1 mice bearing virus-induced LSTRA lymphomas. Paradoxically, animals treated with a relatively high number of tumor cells responded better to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea) (BCNU) than those challenged with a low number of tumor cells. However, the majority of mice subjected to low initial tumor load were cured when they were treated with chemotherapy plus booster injection of CA at a relatively 'late' stage of the disease, i.e., when high tumor load was present in tumor-bearing hosts. It has been shown that this phenomenon, provisionally called high tumor load protection, occurs when the animals are challenged ip but not when they are challenged iv with the tumor and is abolished by total-body γ-irradiation. Moreover, marked host protection can be attained when immunostimulated mice, inoculated iv with lymphoma cells, are subjected to simultaneous challenge with high inocula of the same tumor ip, followed by BCNU administration. These data stress the importance of the peritoneal cavity of successful CA plus drug treatment and suggest that optimal tumor 'antigen load' should be present at the time of CA and/or BCNU administration.",
author = "P. Marconi and A. Cassone and M. Baccarini and L. Tissi and E. Garaci and E. Bonmassar and L. Frati and F. Bistoni",
year = "1983",
language = "English",
volume = "71",
pages = "299--307",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Relationships among tumor load, route of tumor inoculation, and response to immunochemotherapy in a murine lymphoma model

AU - Marconi, P.

AU - Cassone, A.

AU - Baccarini, M.

AU - Tissi, L.

AU - Garaci, E.

AU - Bonmassar, E.

AU - Frati, L.

AU - Bistoni, F.

PY - 1983

Y1 - 1983

N2 - The combined effects of nonspecific immunostimulation with Candida albicans (CA) and chemotherapy were studied in (BALB/cCr x DBA/2Cr)F1 and (C57BL/6Cr x DBA/2Cr)F1 mice bearing virus-induced LSTRA lymphomas. Paradoxically, animals treated with a relatively high number of tumor cells responded better to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea) (BCNU) than those challenged with a low number of tumor cells. However, the majority of mice subjected to low initial tumor load were cured when they were treated with chemotherapy plus booster injection of CA at a relatively 'late' stage of the disease, i.e., when high tumor load was present in tumor-bearing hosts. It has been shown that this phenomenon, provisionally called high tumor load protection, occurs when the animals are challenged ip but not when they are challenged iv with the tumor and is abolished by total-body γ-irradiation. Moreover, marked host protection can be attained when immunostimulated mice, inoculated iv with lymphoma cells, are subjected to simultaneous challenge with high inocula of the same tumor ip, followed by BCNU administration. These data stress the importance of the peritoneal cavity of successful CA plus drug treatment and suggest that optimal tumor 'antigen load' should be present at the time of CA and/or BCNU administration.

AB - The combined effects of nonspecific immunostimulation with Candida albicans (CA) and chemotherapy were studied in (BALB/cCr x DBA/2Cr)F1 and (C57BL/6Cr x DBA/2Cr)F1 mice bearing virus-induced LSTRA lymphomas. Paradoxically, animals treated with a relatively high number of tumor cells responded better to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea) (BCNU) than those challenged with a low number of tumor cells. However, the majority of mice subjected to low initial tumor load were cured when they were treated with chemotherapy plus booster injection of CA at a relatively 'late' stage of the disease, i.e., when high tumor load was present in tumor-bearing hosts. It has been shown that this phenomenon, provisionally called high tumor load protection, occurs when the animals are challenged ip but not when they are challenged iv with the tumor and is abolished by total-body γ-irradiation. Moreover, marked host protection can be attained when immunostimulated mice, inoculated iv with lymphoma cells, are subjected to simultaneous challenge with high inocula of the same tumor ip, followed by BCNU administration. These data stress the importance of the peritoneal cavity of successful CA plus drug treatment and suggest that optimal tumor 'antigen load' should be present at the time of CA and/or BCNU administration.

UR - http://www.scopus.com/inward/record.url?scp=0020572387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020572387&partnerID=8YFLogxK

M3 - Article

C2 - 6348362

AN - SCOPUS:0020572387

VL - 71

SP - 299

EP - 307

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -